{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:00:59Z","timestamp":1785351659852,"version":"3.55.0"},"reference-count":38,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Open Innovations in Science Center of the Ludwig Boltzmann Society"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Growing evidence suggests that mast cell activation (MCA) may contribute to Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS), a debilitating disorder characterized by persistent fatigue and post-exertional malaise (PEM). Particularly in relation to orthostatic intolerance (OI), including postural orthostatic tachycardia syndrome (POTS), this study aimed to investigate the prevalence and clinical relevance of MCA in an Austrian ME\/CFS patient cohort. Methods: Two data sets were analyzed. The CCCFS data set, a comprehensive, patient-centered online questionnaire consisting of 687 filled surveys, focuses on patient stratification. Self-reported clinical features, disease progression, and treatment responses were analyzed. Preliminary findings were validated in a second, retrospective study, analyzing data of 383 Austrian ME\/CFS patients with regard to MCA involvement and OI. Results: Among followed-up ME\/CFS patients, MCA prevalence increased over the disease course, with up to 25.3% meeting the criteria for clinically relevant MCA. ME\/CFS patients with Mast Cell Activation Syndrome (MCAS) and OI reported symptom alleviation significantly more often following mast cell-targeted treatment than those without MCAS (p &lt; 0.0001). With regard to IF-channel inhibitors, ME\/CFS patients diagnosed with MCAS responded more frequently than those without MCAS (p = 0.076), while no significant differences were observed in response to beta blockers (p = 0.637). In both cohorts, OI, particularly POTS, was significantly more common in patients with MCA involvement. Conclusions: MCA appears to be a frequent and clinically relevant comorbidity in ME\/CFS and is associated with a higher prevalence of OI, particularly POTS. Stratifying patients based on MCA involvement may support personalized treatment approaches and improve clinical outcomes.<\/jats:p>","DOI":"10.3390\/diagnostics15222828","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:35:31Z","timestamp":1762770931000},"page":"2828","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Clinical Relevance of Mast Cell Activation in Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-2099","authenticated-orcid":false,"given":"Johanna","family":"Rohrhofer","sequence":"first","affiliation":[{"name":"Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Ebner","sequence":"additional","affiliation":[{"name":"Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schweighardt","sequence":"additional","affiliation":[{"name":"Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stingl","sequence":"additional","affiliation":[{"name":"CerePrax, 1150 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1963-499X","authenticated-orcid":false,"given":"Eva","family":"Untersmayr","sequence":"additional","affiliation":[{"name":"Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12967-020-02269-0","article-title":"Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME)","volume":"18","author":"Lim","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2796.2011.02428.x","article-title":"Myalgic encephalomyelitis: International Consensus Criteria","volume":"270","author":"Carruthers","year":"2011","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1515\/reveh-2015-0026","article-title":"Review of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: An evidence-based approach to diagnosis and management by clinicians","volume":"30","author":"Bested","year":"2015","journal-title":"Rev. Env. Health"},{"key":"ref_4","unstructured":"Hainzl, A., Rohrhofer, J., Schweighardt, J., Hermisson, J., Hoffmann, K., Komenda-Lett, M., Schlaff, G., Schulz, C., Stingl, M., and Thonhofer, K. (2025, September 11). Care for ME\/CFS\u2014Praxisleitfaden f\u00fcr die Versorgung von ME\/CFS Betroffenen. Zenodo. Available online: https:\/\/share.google\/q5AR8MToEKdKCr99G."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12967-019-02196-9","article-title":"Systematic review of randomized controlled trials for chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME)","volume":"18","author":"Kim","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00011-018-1164-5","article-title":"An overview of mast cell pattern recognition receptors","volume":"67","author":"Agier","year":"2018","journal-title":"Inflamm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Glass, K.A., Germain, A., Huang, Y.V., and Hanson, M.R. (2023). Urine Metabolomics Exposes Anomalous Recovery after Maximal Exertion in Female ME\/CFS Patients. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043685"},{"key":"ref_8","first-page":"787","article-title":"Role of TNF in mast cell neuroinflammation and pain","volume":"29","author":"Gu","year":"2015","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"G969","DOI":"10.1152\/ajpgi.00146.2006","article-title":"TNF-alpha is crucial for the development of mast cell-dependent colitis in mice","volume":"291","author":"Rijnierse","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhang, B., Asadi, S., Weng, Z., Sismanopoulos, N., and Theoharides, T.C. (2012). Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049767"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0014-2999(94)90698-X","article-title":"Effect of arginine analogues on rat hind paw oedema and mast cell activation in vitro","volume":"257","author":"Giraldelo","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1365-2249.2002.01918.x","article-title":"Nitric oxide: A regulator of mast cell activation and mast cell-mediated inflammation","volume":"129","author":"Coleman","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dileepan, K.N., Raveendran, V.V., Sharma, R., Abraham, H., Barua, R., Singh, V., Sharma, R., and Sharma, M. (2023). Mast cell-mediated immune regulation in health and disease. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1213320"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-021-02833-2","article-title":"Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS)","volume":"19","author":"Wirth","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23751","DOI":"10.1073\/pnas.1915075117","article-title":"Perinatal androgens organize sex differences in mast cells and attenuate anaphylaxis severity into adulthood","volume":"117","author":"Mackey","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rowe, P.C., Underhill, R.A., Friedman, K.J., Gurwitt, A., Medow, M.S., Schwartz, M.S., Speight, N., Stewart, J.M., Vallings, R., and Rowe, K.S. (2017). Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00121"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1016\/j.mayocp.2021.07.004","article-title":"Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management","volume":"96","author":"Bateman","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.clinthera.2016.04.038","article-title":"A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis","volume":"38","author":"Collatz","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102906","DOI":"10.1016\/j.autneu.2021.102906","article-title":"Salt supplementation in the management of orthostatic intolerance: Vasovagal syncope and postural orthostatic tachycardia syndrome","volume":"237","author":"Williams","year":"2022","journal-title":"Auton. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102951","DOI":"10.1016\/j.autneu.2022.102951","article-title":"Oral and intravenous hydration in the treatment of orthostatic hypotension and postural tachycardia syndrome","volume":"238","author":"Snapper","year":"2022","journal-title":"Auton. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.autneu.2018.04.008","article-title":"Pharmacotherapy for postural tachycardia syndrome","volume":"215","author":"Miller","year":"2018","journal-title":"Auton. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/aap.2021.42.210022","article-title":"The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome","volume":"42","author":"Wang","year":"2021","journal-title":"Allergy Asthma Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.anai.2021.10.006","article-title":"Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy","volume":"128","author":"Novak","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e021002","DOI":"10.1161\/JAHA.121.021002","article-title":"Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association","volume":"10","author":"Kohno","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: Proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijid.2021.09.043","article-title":"Mast cell activation symptoms are prevalent in Long-COVID","volume":"112","author":"Weinstock","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5415\/apallergy.0000000000000022","article-title":"Immunological dysfunction and mast cell activation syndrome in long COVID","volume":"13","author":"Sumantri","year":"2023","journal-title":"Asia Pac. Allergy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000535736","article-title":"Immune Mechanisms Underpinning Long COVID: Collegium Internationale Allergologicum Update 2024","volume":"185","author":"Untersmayr","year":"2024","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_31","unstructured":"National Academy of Sciences (US) (2015). The National Academies Collection: Reports funded by National Institutes of Health. Beyond Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: Redefining an Illness, National Academies Press (US)."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings","year":"2016","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000158259.68614.40","article-title":"Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders","volume":"45","author":"Shibao","year":"2005","journal-title":"Hypertension"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1054-3589(10)59003-3","article-title":"I(f) inhibition in cardiovascular diseases","volume":"59","author":"Thollon","year":"2010","journal-title":"Adv. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2020.12.029","article-title":"Randomized Trial of Ivabradine in Patients with Hyperadrenergic Postural Orthostatic Tachycardia Syndrome","volume":"77","author":"Taub","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ogasawara, H., and Noguchi, M. (2021). Therapeutic Potential of MRGPRX2 Inhibitors on Mast Cells. Cells, 10.","DOI":"10.3390\/cells10112906"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Piotin, A., Oulehri, W., Charles, A.-L., Tacquard, C., Collange, O., Mertes, P.-M., and Geny, B. (2024). Oxidative Stress and Mitochondria Are Involved in Anaphylaxis and Mast Cell Degranulation: A Systematic Review. Antioxidants, 13.","DOI":"10.3390\/antiox13080920"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","article-title":"Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists","volume":"154","author":"Wollam","year":"2024","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/22\/2828\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:48:19Z","timestamp":1762771699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/22\/2828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":38,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["diagnostics15222828"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15222828","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}